Bridgeway Capital Management’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Bridgeway Capital Management’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,539	Closed	-$25.8K	–	1290
2025 Q3	$25.8K	Hold	1,539	–	–	﹤0.01%	1186
2025 Q2	$127K	Buy	1,539 +500	+48%	+$32.5K	﹤0.01%	1035
2025 Q1	$82.1K	Buy	1,039 +300	+41%	+$36.9K	﹤0.01%	1071
2024 Q4	$124K	Buy	+739	New	+$96.7K	﹤0.01%	1085
2020 Q2	–	Sell	-29	Closed	-$283K	–	1406
2020 Q1	$283K	Sell	29 -9	-24%	-$141K	0.01%	948
2019 Q4	$629K	Buy	38 +1	+3%	+$16.7K	0.01%	885
2019 Q3	$596K	Hold	37	–	–	0.01%	877
2019 Q2	$789K	Hold	37	–	–	0.01%	815
2019 Q1	$1.03M	Buy	37 +2	+6%	+$48K	0.01%	754
2018 Q4	$515K	Hold	35	–	–	0.01%	991
2018 Q3	$1.23M	Buy	+35	New	+$1.08M	0.01%	799

Other funds holding YARW

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

T3 Companies New York $93.7M AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's YARW Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q4 2025, closing a stake of 1,539 shares — an estimated $25.8K sold.

Bridgeway Capital Management first reported a position in YARW in Q3 2018 and held it in 11 quarters. The position peaked at $1.23M in Q3 2018. 41 funds tracked by Wall St. Rank hold YARW as of Q4 2025.

Bridgeway Capital Management reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
Bridgeway Capital Management sold 1,539 Yarrow Bioscience, Inc. Common Stock shares in Q4 2025, an estimated $25.8K.
Bridgeway Capital Management first reported a position in Yarrow Bioscience, Inc. Common Stock in Q3 2018 and held it in 11 quarters.
Bridgeway Capital Management's Yarrow Bioscience, Inc. Common Stock position peaked at $1.23M in Q3 2018.
41 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.